A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world Data
<p dir="ltr">A high-intensity statin is recommended for the secondary prevention of cardiovascular diseases (CVD). However, real-world evidence of the effectiveness of rosuvastatin following acute coronary syndrome (ACS) is scarce. This retrospective cohort study included patients di...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , , , , |
| Published: |
2022
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513547801722880 |
|---|---|
| author | Alaa Rahhal (14150403) |
| author2 | Fadi Khir (14150406) Bassant Orabi (17269123) Salma Chbib (17269126) Osama Al-Khalaila (17269129) Mohamed Salah Abdelghani (16810758) Omnia Osman (17269132) Amr Azzam Ashour (17269135) Mohammad Al-Awad (17191867) Ahmed Mahfouz (737928) Ahmed Awaisu (5121473) Amer Hussien Aljundi (14150409) Yaser Alahmad (17269138) Sumaya Alyafei (14147868) Abdul Rahman Arabi (12506942) |
| author2_role | author author author author author author author author author author author author author author |
| author_facet | Alaa Rahhal (14150403) Fadi Khir (14150406) Bassant Orabi (17269123) Salma Chbib (17269126) Osama Al-Khalaila (17269129) Mohamed Salah Abdelghani (16810758) Omnia Osman (17269132) Amr Azzam Ashour (17269135) Mohammad Al-Awad (17191867) Ahmed Mahfouz (737928) Ahmed Awaisu (5121473) Amer Hussien Aljundi (14150409) Yaser Alahmad (17269138) Sumaya Alyafei (14147868) Abdul Rahman Arabi (12506942) |
| author_role | author |
| dc.creator.none.fl_str_mv | Alaa Rahhal (14150403) Fadi Khir (14150406) Bassant Orabi (17269123) Salma Chbib (17269126) Osama Al-Khalaila (17269129) Mohamed Salah Abdelghani (16810758) Omnia Osman (17269132) Amr Azzam Ashour (17269135) Mohammad Al-Awad (17191867) Ahmed Mahfouz (737928) Ahmed Awaisu (5121473) Amer Hussien Aljundi (14150409) Yaser Alahmad (17269138) Sumaya Alyafei (14147868) Abdul Rahman Arabi (12506942) |
| dc.date.none.fl_str_mv | 2022-07-07T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.cpcardiol.2021.100956 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/A_Comparative_Study_of_High-intensity_Rosuvastatin_Versus_Atorvastatin_Therapy_Post-acute_Coronary_Syndrome_Using_Real-world_Data/24420472 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Cardiovascular diseases High-intensity statin therapies Rosuvastatin Atorvastatin Acute coronary syndrome |
| dc.title.none.fl_str_mv | A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world Data |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">A high-intensity statin is recommended for the secondary prevention of cardiovascular diseases (CVD). However, real-world evidence of the effectiveness of rosuvastatin following acute coronary syndrome (ACS) is scarce. This retrospective cohort study included patients diagnosed with ACS to compare between the 2 high-intensity statin therapies (rosuvastatin vs atorvastatin) in terms of a primary composite outcome of CVD-associated death, non-fatal ACS, and non-fatal stroke at 1 month and 12 months post discharge. The primary effectiveness outcome did not differ between the 2 groups at 1 month (1.3% vs 1%; aHR = 1.64, 95% CI 0.55-4.94, P= 0.379) and at 12 months (4.8% vs 3.5%; aHR = 1.48, 95% CI 0.82-2.67, P= 0.199). Similarly, the 2 groups had comparable safety outcomes. In conclusion, the use of high-intensity rosuvastatin compared to high-intensity atorvastatin therapy in patients with ACS had resulted in comparable cardiovascular effectiveness and safety outcomes.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2021.100956" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2021.100956</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_4e568c2555564584d25f47d065bf712a |
| identifier_str_mv | 10.1016/j.cpcardiol.2021.100956 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/24420472 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world DataAlaa Rahhal (14150403)Fadi Khir (14150406)Bassant Orabi (17269123)Salma Chbib (17269126)Osama Al-Khalaila (17269129)Mohamed Salah Abdelghani (16810758)Omnia Osman (17269132)Amr Azzam Ashour (17269135)Mohammad Al-Awad (17191867)Ahmed Mahfouz (737928)Ahmed Awaisu (5121473)Amer Hussien Aljundi (14150409)Yaser Alahmad (17269138)Sumaya Alyafei (14147868)Abdul Rahman Arabi (12506942)Biomedical and clinical sciencesCardiovascular medicine and haematologyPharmacology and pharmaceutical sciencesCardiovascular diseasesHigh-intensity statin therapiesRosuvastatinAtorvastatinAcute coronary syndrome<p dir="ltr">A high-intensity statin is recommended for the secondary prevention of cardiovascular diseases (CVD). However, real-world evidence of the effectiveness of rosuvastatin following acute coronary syndrome (ACS) is scarce. This retrospective cohort study included patients diagnosed with ACS to compare between the 2 high-intensity statin therapies (rosuvastatin vs atorvastatin) in terms of a primary composite outcome of CVD-associated death, non-fatal ACS, and non-fatal stroke at 1 month and 12 months post discharge. The primary effectiveness outcome did not differ between the 2 groups at 1 month (1.3% vs 1%; aHR = 1.64, 95% CI 0.55-4.94, P= 0.379) and at 12 months (4.8% vs 3.5%; aHR = 1.48, 95% CI 0.82-2.67, P= 0.199). Similarly, the 2 groups had comparable safety outcomes. In conclusion, the use of high-intensity rosuvastatin compared to high-intensity atorvastatin therapy in patients with ACS had resulted in comparable cardiovascular effectiveness and safety outcomes.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2021.100956" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2021.100956</a></p>2022-07-07T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.cpcardiol.2021.100956https://figshare.com/articles/journal_contribution/A_Comparative_Study_of_High-intensity_Rosuvastatin_Versus_Atorvastatin_Therapy_Post-acute_Coronary_Syndrome_Using_Real-world_Data/24420472CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/244204722022-07-07T00:00:00Z |
| spellingShingle | A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world Data Alaa Rahhal (14150403) Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Cardiovascular diseases High-intensity statin therapies Rosuvastatin Atorvastatin Acute coronary syndrome |
| status_str | publishedVersion |
| title | A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world Data |
| title_full | A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world Data |
| title_fullStr | A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world Data |
| title_full_unstemmed | A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world Data |
| title_short | A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world Data |
| title_sort | A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world Data |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Cardiovascular diseases High-intensity statin therapies Rosuvastatin Atorvastatin Acute coronary syndrome |